Biosimilars Biosimilar products, which have been circulating in Europe for about a decade, have emerged as a new category of drug within the USA’s pharmaceutical market – a trend underscored by the Food and Drug Administration’s (FDA) approval of five new biosimilars since 2015 - writes Rich Tremonte, senior vice president of global generic pharmaceuticals at drug wholesaler AmerisourceBergen, in an expert view piece. 10 May 2017